A Feasibility Study: A Safety Evaluation of the Gala Airway Treatment System on Patients with Chronic Bronchitis in Australia
Not Applicable
Recruiting
- Conditions
- BronchitisEmphysema
- Registration Number
- ACTRN12617000330347
- Lead Sponsor
- Gala Therapeutics Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways does the Gala Airway Treatment System target in chronic bronchitis and emphysema patients?
How does the Gala Airway Treatment System compare to inhaled corticosteroids in COPD exacerbation prevention?
Which biomarkers correlate with improved airway function in ACTRN12617000330347 COPD trials?
What adverse events are associated with bronchial thermoplasty in chronic bronchitis/emphysema populations?
Are there alternative bronchodilator therapies with similar safety profiles to the Gala Airway Treatment System?